David Tsao

Co-founder and CTO at BillionToOne.

[BillionToOne @BillionToOneInc]

You might notice we look a little different today as we've rolled out a fresh new look. But our values and mission remain the same. Check out our website: https://t.co/AixJqipfr7

Curious about our name? Watch this 1 min video: https://t.co/6cmUTzvH1S

https://t.co/IXsV09MaoT

[BillionToOne @BillionToOneInc]

We are thrilled to announce the closure of our #SeriesC funding round with premier global investors. $125M to help us continue to grow our team and move #nipt and #liquidbiopsy forward. https://t.co/iVFgwcKcuv

[BillionToOne @BillionToOneInc]

Congrats, Nancy!

[BillionToOne @BillionToOneInc]

BillionToOne Closes $55M Series B Funding, Builds Out a 36,000 Sqft Space to Meet Growing Demand https://t.co/s0aB6jRCNq

[David Tsao @dtsao]

Our preprint describing this work is now available on biorxiv: https://t.co/xnsgKfCxVT

[David Tsao @dtsao]

We’ve been working hard @BillionToOne on a new COVID-19 test that scales testing to everyone in the US https://t.co/izvVyc7TJm.
It (1) re-purposes existing infrastructure, (2) eliminates time-consuming RNA extraction, and (3) enables a distributed system for COVID-19 testing.

[David Tsao @dtsao]

Thanks to the BillionToOne team for all the hard work pulling this together! Next step is to start manufacturing test kits and obtain Emergency Use Authorization from the FDA. If you're a Lab Director or contract kit manufacturer, we're looking for partners.

[David Tsao @dtsao]

@NathanGrubaugh We’re working on using Sanger sequencing to do thousands of tests per day, per instrument. https://t.co/tkBMDCBXwY

[David Tsao @dtsao]

@zaid CLIA rules that dictate that all analytic processing must happen end-to-end within a single CLIA-certified lab.